Description

Fulvestrant is the first-in-class selective estrogen receptor degrader (SERD) used primarily in the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women. As a high-affinity estrogen receptor antagonist, it promotes ER degradation and inhibits estrogen-driven tumor growth.

Formulated by EVER Pharma Jena GmbH under the NMPA drug standard code HJ20250032, each pre-filled syringe delivers 250mg/5ml. The German-manufactured product mirrors Bayer’s Faslodex® and is suitable for research covering:

• ER-positive breast cancer models

• Preclinical studies on endocrine therapy resistance

• Combination studies with CDK4/6 inhibitors (e.g., palbociclib)

Fulvestrant Product Specifications

Fulvestrant Mechanism & Pharmacology

• SERD activity: Binds estrogen receptors, accelerates their degradation, and halts estrogen-driven cell proliferation.

• Pharmacokinetics: IM injection results in peak concentration at ~5 days post-dose, with a prolonged half-life of ~40–50 days.

• Protein binding & metabolism: Highly protein-bound (~99%), metabolized via CYP3A4 and non-CYP pathways; primarily excreted in feces.

• Synergistic use: Commonly used in combination studies with CDK4/6 inhibitors like palbociclib or abemaciclib.

Why Choose EVER Pharma Fluvestrant?

• High-quality automotive formulation with strong regulatory backing

• Ideal for advanced oncology and endocrine research

• Long half-life supports extended dosing models

• Pre-filled syringes offer convenience and reproducibility in dosing

Related Research Agents

• Abemaciclib or Palbociclib (CDK4/6 inhibitors)

• Tamoxifen / Exemestane (ER modulators/aromatase inhibitors)

• Newer oral SERDs (e.g., elacestrant)

Summary

Fulvestrant (250mg/5ml) by EVER?Pharma is a trusted SERD for oncology research models. With reliable pharmacokinetics, pre-filled syringes, and regulatory consistency, it’s suited for advanced cancer research settings.